Genovation BioScience is a clinical-stage health care company with a chemistry driven approach to leveraging breakthrough protein science to treat disease and improve human health. We utilize cutting edge artificial intelligence and data management to optimize the discovery and approval of new therapeutics and research tools.
The engineering of enzymes, antibody therapeutics, and biosynthesis pathways have benefited greatly from developments in directed evolution, whose pioneers were awarded the 2018 Nobel Prize in Chemistry. Directed evolution induces artificial evolutionary forces on proteins and biosynthesis pathways with the aim of optimizing or changing their properties, such as stability, activity, or binding affinity. Traditionally, directed evolution designs call for the screening of thousands to millions of protein variants. The application of these powerful methods have thus been limited to experiments which are suitable for high-throughput, inexpensive screens.
We have developed widely extensible deep learning models to lower the screening costs of directed evolution, thereby easing its key bottleneck, by incorporating advances in deep learning which have to date been unrealized in the biological sciences. In particular, we have combined two innovations which have seen a history of success in deep learning applications:
We have developed significantly larger and more powerful protein language models than previously applied in protein engineering
We have combined these language models with state of art search techniques like reinforcement learning and adaptive evolutionary search to efficiently generate protein sequences with optimized performance
We are currently focused on applications of our models towards the engineering of antibody molecules. Antibody therapeutics are a rapidly developing class of therapeutic molecules known for safety, efficacy, and commercial impact, with annual sales now exceeding $120bn. To reduce development costs and engineer more sophisticated antibody functions, it is imperative to engineer multiple properties related to antibody safety (ie immunogenicity or stability), efficacy (ie binding affinity or target neutralization), and ease of manufacturing (ie aggregation propensity or expressibility). However, engineering of these multiple competing objectives is complicated by the fact the optimization of any one of these properties may antagonize the status of others.
To increase the efficiency of antibody development, we have developed the first models capable of generating antibody molecules which are simultaneously optimized for binding affinity and favorable developability characteristics. In addition, we have developed models to support the engineering of antibodies with conventionally difficult to engineer, novel biological functionalities including multispecificity and pH-dependent binding, with ultimate applications towards tuning antibody tumor specificity, half-lives, and/or antigen clearance.
Chief Technical Officer
Michael Jemison earned his PhD in mathematics from Princeton University in 2020. As a mathematician, Michael's research interests centered around topology and geometry. Now he is excited to leverage mathematics in the applied sciences. In particular, his interests include machine learning, AI, and data mining with an eye towards applications to real world evidence and drug discovery.
Laurence Berger brings to the Company significant experience in strategic and operational leadership both in and out of the finance function.
From his early employment at the dawn of the biotech era under the supervision of the late Raymond Vernon at Harvard Business School, Larry has contributed to the expansion of the creation and understanding of the life sciences. Previously, he served as a key member of the corporate finance group at LF Rothschild Unterberg Towbin that managed the initial public offerings of the newly incubated companies Cetus Corp. and Genentech. Over the last forty years, he has advised a number of international corporate efforts and joint ventures in the field. Amongst many transactions, he organized the efforts at Rhone Poulenc s.a. that led to the creation of Sanofi-Aventis.
For twenty five years he was the Managing Partner of Vanderbilt Associates, an advisory firm and early stage private equity private firm. Subsequent to that experience, he was CEO and President of Thames Pharmacal, a manufacturer of both new drug and generic drugs with over 90 NDA and ANDA approvals.
Larry served as Senior Adviser to Cromwell Enterprises L.P., a private equity investment firm, from 2007 to 2016. Currently, he is Executive Partner of Berger Group International.
He serves of the Task Force on Science and Engineering at Harvard University in addition to his responsibilities at the Harvard Alumni Association. He also serves on the non profit boards of the First Step Initiatives and the Nature Conservancy.
Larry derives deep satisfaction from a life long passion for great music and a quest of some 55 years to hit a little round ball into holes in the illusive firmament of the countryside. He has followed that quest on five continents. Always with a caring dog at this side, he is the proud Dad of three wonderful children.